1. Octreotide Versus Octreotide Plus Interferon-Alpha in Endocrine Gastroenteropancreatic Tumors: A Randomized Trial 
Rudolf Arnold, Anja Rinke, Klaus-Jochen Klose, Hans-Helge Müller, Matthias Wied, Karin Zamzow, Christina Schmidt, Carmen Schade- Brittinger, Peter Barth, Roland Moll, Michael Koller, Michael Unterhalt, Wolfgang Hiddemann, Martin Schmidt-Lauber, Marianne Pavel, Christian N. Arnold 
Clinical Gastroenterology and Hepatology 
Volume 3, Issue 8, Pages (August 2005)
DOI: /S (05)
Copyright © 2005 American Gastroenterological Association Terms and Conditions

2. Figure 1
Trial profile.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

3. Figure 2
Intention to treat analysis of survival in 51 patients receiving octreotide monotherapy (solid line) and in 54 patients receiving octreotide plus interferon alpha (dotted line). After 6 months 50% of patients in either group had an event terminating the study treatment (P = .59). Vertical lines (|) indicate censoring, which means after a patient’s last follow up, no further information on the patient was available.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

4. Figure 3
Intention to treat analysis of survival in 51 patients receiving octreotide monotherapy (solid line) and in 54 patients receiving octreotide plus interferon-alpha (dotted line) (P = .38). Nine patients have not been randomized (broken line) (P = .083 vs randomized patients). Vertical lines (|) indicate censoring, which means after a patient’s last follow up, no further information on the patient was available.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

5. Figure 4
Survival of 47 patients with stable disease before randomization of >6 months (solid line) versus 66 patients with stable disease before randomization of ≤6 months (dotted line). (Exploratory analysis, P = .06.) Vertical lines (|) indicate censoring, which means after a patient’s last follow up, no further information on the patient was available.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

6. Figure 5
Survival of 31 patients with stable disease or partial regression at 6 months of treatment with monotherapy or combination treatment (solid line) versus survival in 44 patients with tumor progression (dotted line). (P = .0057). Vertical lines (|) indicate censoring, which means after a patient’s last follow up, no further information on the patient was available.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

7. Figure 6
Survival of 37 patients with low Ki-67 (solid line) versus 31 patients with high Ki-67 (broken line). (P = .0292). Vertical lines (|) indicate censoring, which means after a patient’s last follow up, no further information on the patient was available.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions